BlackRock Fund Advisors recently announced the acquisition of new stake in ADMA Biologics Inc. (NASDAQ:ADMA). The institutional investor has increased its shareholding in the Healthcare company by 8.94% to 5.21 million shares with purchase of 0.43 million shares. This fresh investment now brings its stake to 6.04% valued currently at $18.6 million. In addition, Sphera Funds Management Ltd. raised its holdings by 0.15 million to 1.98 million shares. And Prosight Management LP has lifted its position by 4.55% or 56600.0 shares – to 1.3 million shares.
With over 4.17 million ADMA Biologics Inc. (ADMA) shares trading Friday and a closing price of $2.74 on the day, the dollar volume was approximately $11.43 million. The shares have shown a positive weekly performance of 8.93% and its price on 08/28/20 lost nearly -0.18%. Currently, there are 86.35M common shares owned by the public and among those 62.75M shares have been available to trade.
Incidentally, analysts’ outlook for the ADMA Biologics Inc. stock is 1.70 for the next 12 months.
Insiders at the company have transacted a total of 31 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 31 of these insider trades were purchases, accounting for 5,486,055 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in ADMA Biologics Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 2.09 million shares of the company’s stock, all valued at over $7.45 million. iShares Russell 2000 ETF sold 58310.0 shares to see its total holdings shrink to 1.25 million shares valued at over $4.45 million and representing 1.44% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 1.15% of the shares outstanding.
Shares of ADMA Biologics Inc. (NASDAQ: ADMA) opened at $2.75, unchanged from a prior closing price of $2.75. However, the script later closed the day at $2.74, down -0.18%. The company’s stock has a 5-day price change of 8.93% and -10.29% over the past three months. ADMA shares are trading -31.38% year to date (YTD), with the 12-month market performance down to -37.90% lower. It has a 12-month low price of $1.45 and touched a high of $5.48 over the same period. Currently, 4.17 million shares have been traded, compared to an average intraday trading volume of 5.88 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.66%, -7.85%, and -17.05% respectively.
Institutional ownership of ADMA Biologics Inc. (NASDAQ: ADMA) shares accounts for 62.90% of the company’s 86.35M shares outstanding. Mutual fund holders own 26.93%, while other institutional holders and individual stakeholders account for 43.79% and 12.88% respectively.
It has a market capitalization of $237.50M and a beta (3y monthly) value of 2.03. The earnings-per-share (ttm) stands at -$0.87. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.27% over the week and 9.12% over the month.
Analysts forecast that ADMA Biologics Inc. (ADMA) will achieve an EPS of -$0.19 for the current quarter, -$0.17 for the next quarter and -$0.47 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.19 a year ago. Earnings per share for the fiscal year are expected to increase by 38.90%, and 44.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate ADMA Biologics Inc. (ADMA) as a “Strong Buy” at a consensus score of 1.70. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ADMA, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on June 04, 2019, with the firm’s price target at $8. H.C. Wainwright coverage for the ADMA Biologics Inc. (ADMA) stock in a research note released on April 15, 2019 offered a Buy rating with a price target of $13. H.C. Wainwright was of a view on February 07, 2019 that the stock is Buy, while Maxim Group gave the stock Buy rating on December 11, 2017, issuing a price target of $13- $8. Raymond James on their part issued Outperform rating on November 14, 2017.